Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 10/20 | 0.51 |
| ▸ | PPARA | Q07869 | 9/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | PPARD | Q03181 | 3/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | MMP1 | P03956 | 1/20 | 0.44 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2524843 | 1.00 | PPARG (0.51) | PPARGPPARAPTPN1PPARDCYP2C9 | |
| SCHEMBL2518481 | 0.96 | PPARG (0.50) | PPARGPPARAPTPN1PPARDCYP2C9 | |
| SCHEMBL2518483 | 0.96 | PPARG (0.50) | PPARGPPARAPTPN1PPARDCYP2C9 | |
| SCHEMBL2520054 | 0.93 | PPARG (0.52) | PPARGPPARACYP2C9KCNH2FFAR1 | |
| SCHEMBL2520051 | 0.93 | PPARG (0.52) | PPARGPPARACYP2C9KCNH2FFAR1 | |
| SCHEMBL2517508 | 0.92 | PPARA (0.52) | PPARGPPARAMAPTFFAR1MMP1 | |
| SCHEMBL2517504 | 0.92 | PPARA (0.52) | PPARGPPARAMAPTFFAR1MMP1 | |
| SCHEMBL2521135 | 0.90 | FFAR1 (0.55) | PPARGPPARAMAPTFFAR1MMP1 | |
| SCHEMBL2521132 | 0.90 | FFAR1 (0.55) | PPARGPPARAMAPTFFAR1MMP1 | |
| SCHEMBL2521659 | 0.89 | PPARG (0.57) | PPARGPPARACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110251171-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | BACH ANDREW THOMAS | 2011-10-13 | — | — | US | claimed |
| US-20090118160-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | BACH ANDREW THOMAS | 2009-05-07 | — | — | US | claimed |
| US-20080131475-A1 | Methods of Use of Dual Ppar Agonist Compounds and Drug Delivery Devices Containing Such Compounds | COHEN DAVID SAUL | 2008-06-05 | — | — | US | claimed |
| EP-1448523-B1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | NOVARTIS AG (CH) | 2007-08-22 | — | — | EP | claimed |
| US-20070135502-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | BACH ANDREW T | 2007-06-14 | — | — | US | claimed |
| US-20040248936-A1 | Heterocyclic compounds and methods of use | BACH ANDREW THOMAS (US) | 2004-12-09 | — | — | US | claimed |
| EP-1448523-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Novartis AG (CH) | 2004-08-25 | — | — | EP | claimed |
| WO-2003043985-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | NOVARTIS AG (CH) | 2003-05-30 | — | — | WO | claimed |
| US-20110251171-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | BACH ANDREW THOMAS | 2011-10-13 | — | — | US | disclosed |
| US-20090118160-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | BACH ANDREW THOMAS | 2009-05-07 | — | — | US | disclosed |
| US-20080131475-A1 | Methods of Use of Dual Ppar Agonist Compounds and Drug Delivery Devices Containing Such Compounds | COHEN DAVID SAUL | 2008-06-05 | — | — | US | disclosed |
| EP-1841422-A1 | METHODS OF USE OF DUAL PPAR AGONIST COMPOUNDS AND DRUG DELIVERY DEVICES CONTAINING SUCH COMPOUNDS | Novartis AG (CH) | 2007-10-10 | — | — | EP | disclosed |
| EP-1448523-B1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | NOVARTIS AG (CH) | 2007-08-22 | — | — | EP | disclosed |
| US-20070135502-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | BACH ANDREW T | 2007-06-14 | — | — | US | disclosed |
| US-7183304-B2 | such as (R)-1-{4-[4-(4-Phenoxy-2-propyl-phenoxy)-butoxy]-benzenesulfonyl}-azetidine-2-carboxylic acid, used as peroxisome proliferator-activated receptor agonists; hypoglycemic agents | NOVARTIS AG (CH) | 2007-02-27 | — | — | US | disclosed |
| WO-2006084757-A2 | COMBINATION OF CA/MG SALT OF VALSARTAN WITH AN ANTIDIABETIC AGENT | NOVARTIS AG (CH) | 2006-08-17 | — | — | WO | disclosed |
| WO-2006078605-A1 | METHODS OF USE OF DUAL PPAR AGONIST COMPOUNDS AND DRUG DELIVERY DEVICES CONTAINING SUCH COMPOUNDS | NOVARTIS AG (CH) | 2006-07-27 | — | — | WO | disclosed |
| US-20040248936-A1 | Heterocyclic compounds and methods of use | BACH ANDREW THOMAS (US) | 2004-12-09 | — | — | US | disclosed |
| EP-1448523-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Novartis AG (CH) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003043985-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | NOVARTIS AG (CH) | 2003-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118160-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | PPARG, PPARA, PPARD | PPARG 1/4885PPARA 2/4885PTPN1 1805/4885 |
| US-20040248936-A1 | Heterocyclic compounds and methods of use | PPARG, GPR119, PPARD | PPARG 1/4885PPARA 4/4885PTPN1 1655/4885 |
| US-20110251171-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | PPARG, PPARA, PPARD | PPARG 1/4885PPARA 2/4885PTPN1 1805/4885 |
| US-20070135502-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | PPARG, PPARA, PPARD | PPARG 1/4885PPARA 2/4885PTPN1 1805/4885 |
| US-20080131475-A1 | Methods of Use of Dual Ppar Agonist Compounds and Drug Delivery Devices Containing Such Compounds | PPARA, PPARD, PPARG | PPARG 3/4885PPARA 1/4885PTPN1 2922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.